IMIDAPRIL

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H27N3O6
Molecular Weight	405.4449
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@@H](CN(C)C2=O)C(O)=O

InChI

InChIKey=KLZWOWYOHUKJIG-BPUTZDHNSA-N

InChI=1S/C20H27N3O6/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26)/t13-,15-,16-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C20H27N3O6
Molecular Weight	405.4449
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.drugs.com/uk/pdf/leaflet/815031.pdf
Curator's Comment: Description was created based on several sources, including https://www.medicines.org.uk/emc/medicine/31738 http://patient.info/medicine/imidapril-for-high-blood-pressure-tanatril https://www.ncbi.nlm.nih.gov/pubmed/17547476

Imidapril (Tanatril), through its active metabolite imidaprilat, acts as an ACE inhibitor to suppress the conversion of angiotensin I to angiotensin II and thereby reduce total peripheral resistance and systemic blood pressure (BP). In clinical trials, oral imidapril was an effective antihypertensive agent in the treatment of mild to moderate essential hypertension. Some evidence suggests that imidapril also improves exercise capacity in patients with chronic heart failure (CHF) and reduces urinary albumin excretion rate in patients with type 1 diabetes mellitus. Imidapril was well tolerated, with a lower incidence of dry cough than enalapril or benazepril, and is a first choice ACE inhibitor for the treatment of mild to moderate essential hypertension.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Angiotensin-converting enzyme 94 Target ID: CHEMBL2096989 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18192036 \| https://www.ncbi.nlm.nih.gov/pubmed/8923331	Inhibitor 8504
Angiotensin-converting enzyme 94 Target ID: CHEMBL1808 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1322856 \| https://www.ncbi.nlm.nih.gov/pubmed/10480327	Inhibitor 8504		9.9 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 575 Sources: https://www.drugs.com/uk/pdf/leaflet/815031.pdf	Primary		Approved 8583	Tanatril Approved Use Tanatril is indicated for the treatment of essential hypertension in adults Launch Date 2007

C_max

Value	Dose	Analyte	Population
28.9 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMIDAPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
27.1 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMIDAPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
7.8 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMIDAPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
20.3 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMIDAPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
21.6 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	5 mg 1 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMIDAPRIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
18.6 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMIDAPRIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
7.2 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	5 mg 1 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMIDAPRILAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
18.1 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMIDAPRILAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
31.5 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	10 mg 1 times / hour multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMIDAPRIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
31.8 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMIDAPRIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
23.7 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMIDAPRILAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
47.8 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMIDAPRILAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
36.1 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400315_2144008F1021_1_090_1F.pdf#page=25	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	IMIDAPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
18.6 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400315_2144008F1021_1_090_1F.pdf#page=25	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	IMIDAPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
34.3 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400315_2144008F1021_1_090_1F.pdf#page=25	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	IMIDAPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
12 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400315_2144008F1021_1_090_1F.pdf#page=25	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	IMIDAPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

AUC

Value	Dose	Analyte	Population
113.3 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMIDAPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
113.6 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMIDAPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
107.8 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMIDAPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
246.6 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMIDAPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
112 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	5 mg 1 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMIDAPRIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
107.2 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMIDAPRIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
103.9 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	5 mg 1 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMIDAPRILAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
337.4 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMIDAPRILAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
183.3 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	10 mg 1 times / hour multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMIDAPRIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
188.7 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMIDAPRIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
361 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMIDAPRILAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
818.7 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMIDAPRILAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
168.4 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400315_2144008F1021_1_090_1F.pdf#page=25	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	IMIDAPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
197.1 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400315_2144008F1021_1_090_1F.pdf#page=25	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	IMIDAPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
124.3 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400315_2144008F1021_1_090_1F.pdf#page=25	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	IMIDAPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
137 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400315_2144008F1021_1_090_1F.pdf#page=25	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	IMIDAPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

T_1/2

Value	Dose	Analyte	Population
1.7 h OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMIDAPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.6 h OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMIDAPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
14.8 h OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMIDAPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
7.6 h OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMIDAPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.8 h OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	5 mg 1 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMIDAPRIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.4 h OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMIDAPRIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
17.7 h OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMIDAPRILAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.5 h OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	10 mg 1 times / hour multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMIDAPRIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.5 h OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMIDAPRIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
20.6 h OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMIDAPRILAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
12.4 h OTHER GOV'T https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMIDAPRILAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1.94 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400315_2144008F1021_1_090_1F.pdf#page=25	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	IMIDAPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.83 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400315_2144008F1021_1_090_1F.pdf#page=25	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	IMIDAPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.78 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400315_2144008F1021_1_090_1F.pdf#page=25	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	IMIDAPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
6.85 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400315_2144008F1021_1_090_1F.pdf#page=25	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	IMIDAPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

F_unbound

Value	Dose	Co-administered	Analyte	Population
15% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400315_2144008F1021_1_090_1F.pdf#page=26			IMIDAPRIL plasma	Homo sapiens
49% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400315_2144008F1021_1_090_1F.pdf#page=26			IMIDAPRILAT plasma	Homo sapiens

Doses

Dose	Population	Adverse events
40 mg 1 times / day multiple, oral Higher than recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8198936/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/8198936/	Disc. AE: Nervousness, Palpitations... Other AEs: Vomiting... AEs leading to discontinuation/dose reduction: Nervousness (3.1%) Palpitations (3.1%) Other AEs: Vomiting (3.1%) Sources: https://pubmed.ncbi.nlm.nih.gov/8198936/
5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11474160/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/11474160/	Sources: https://pubmed.ncbi.nlm.nih.gov/11474160/

AEs

AE	Significance	Dose	Population
Vomiting	3.1%	40 mg 1 times / day multiple, oral Higher than recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8198936/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/8198936/
Nervousness	3.1% Disc. AE	40 mg 1 times / day multiple, oral Higher than recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8198936/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/8198936/
Palpitations	3.1% Disc. AE	40 mg 1 times / day multiple, oral Higher than recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8198936/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/8198936/

PubMed

Title	Date	PubMed
Imidapril: a review of its use in essential hypertension, Type 1 diabetic nephropathy and chronic heart failure.	2007	17547476
Imidapril in heart failure.	2006-09	17094051
[Studies on angiotensin I converting enzyme (ACE) inhibitory effect of imidapril. (I). Inhibition of various tissue ACEs in vitro].	1992-07	1322856

Patents

Sample Use Guides

In Vivo Use Guide

Adult: PO Initial: 5 mg once daily at bedtime. Maintenance: 10 mg/day. Max: 20 mg/day. Should be taken on an empty stomach. Take 15 min before meals. However, when initiating therapy, 1st dose should be given at bedtime.

Route of Administration: Oral

In Vitro Use Guide

Imidapril inhibited activity on Angiotensin I converting enzyme (ACE) obtained from pig renal cortex with IC50 9.9uM

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:25:03 GMT 2025` Edited by `admin` on `Mon Mar 31 18:25:03 GMT 2025`
Record UNII	BW7H1TJS22
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IMIDAPRIL

Official Name

English

HIPERTENE

Preferred Name

English

IMIDAPRIL [MI]

Common Name

English

imidapril [INN]

Common Name

English

Imidapril [WHO-DD]

Common Name

English

(S)-3-(N-((S)-1-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANYL)-1-METHYL-2-OXOIMIDAZOLINE-4-CARBOXYLIC ACID

Systematic Name

English

Classification Tree Code System Code

WHO-ATC

C09AA16